Pharma Focus Asia

CordenPharma & GE Healthcare Offer Unique End-to-End Solution to Accelerate Oligonucleotide Drug Development

Thursday, June 29, 2017

CordenPharma International and GE Healthcare’s Dharmacon business have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery.

The collaboration will address the speed and capacity challenges researchers face when transitioning from research and preclinical stages to drug development and clinical trials. This changeover requires customers to move from a technology vendor to a contract manufacturing organization; compounding this step are capacity challenges in the biotech contract manufacturing marketplace. The collaboration between CordenPharma and GE Healthcare Dharmacon will provide biotech and pharmaceutical customers with a new option to address these challenges.

“Through this agreement, we are bringing GE Healthcare’s Dharmacon product line, which offers leading technical expertise in research-scale design and manufacturing, together with CordenPharma’s deep experience in contract manufacturing,” said Olivier Loeillot, General Manager of GE Healthcare’s Genomics & Cellular Research business. “We can help customers move faster by working together and provide an offering that takes them from bench to batch with one partner.”

CordenPharma International VP of Global Marketing & Sales Michael Quirmbach commented, “This collaboration will further strengthen our newly created service offering in the Oligonucleotide manufacturing field and will uniquely position CordenPharma and Dharmacon in this growing pharmaceutical market segment. Customers will be able to benefit from an efficient end-to-end solution, including drug product supply.

Dharmacon is part of the GE Healthcare Life Sciences division with +20 years of experience in custom synthesis of complex RNA oligonucleotides, including very long lengths (>100 nt) and a very broad range of chemical modifications to support research and pre-clinical capacity. The Dharmacon product line includes an extensive portfolio of CRISPR-Cas9 reagents for targeted gene knockout and knock-in studies, as well as a market-leading suite of siRNA reagents for RNA interference.

CordenPharma entered the Oligonucleotide manufacturing field in 2016 by investing in process development, scale-up and cGMP manufacturing at multiple scales in CordenPharma Colorado, where they are currently supporting early stage to clinical phases II / III, with commercial supply capabilities expected to be operational by the end of 2017. The expansion into the oligonucleotide market, which was triggered by an increasingly rich pipeline in the oligonucleotides field, represents a logical move for CordenPharma within their current API and Drug Product offerings and is considered to be synergistic and complementary to their outstanding experience in manufacturing synthetic peptides, lipids and carbohydrates at multiple CordenPharma facilities.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024